Background Few cross-sectional studies involving adults and elderly patients with major DDIs have been conducted in the primary care setting. The study aimed to investigate the prevalence of potential drug-drug interactions (DDIs) in patients treated in primary care. Methodology/Principal Findings A cross-sectional study involving patients aged 45 years or older was conducted at 25 Basic Health Units in the city of Maringá (southern Brazil) from May to December 2010. The data were collected from prescriptions at the pharmacy of the health unit at the time of the delivery of medication to the patient. After delivery, the researcher checked the electronic medical records of the patient. A total of 827 patients were investigated (mean age: 64.1; mean number of medications: 4.4). DDIs were identified in the Micromedex？ database. The prevalence of potential DDIs and major DDIs was 63.0% and 12.1%, respectively. In both the univariate and multivariate analyses, the number of drugs prescribed was significantly associated with potential DDIs, with an increasing risk from three to five drugs (OR = 4.74; 95% CI: 2.90–7.73) to six or more drugs (OR = 23.03; 95% CI: 10.42–50.91). Forty drugs accounted for 122 pairs of major DDIs, the most frequent of which involved simvastatin (23.8%), captopril/enalapril (16.4%) and fluoxetine (16.4%). Conclusions/Significance This is the first large-scale study on primary care carried out in Latin America. Based on the findings, the estimated prevalence of potential DDIs was high, whereas clinically significant DDIs occurred in a smaller proportion. Exposing patients to a greater number of prescription drugs, especially three or more, proved to be a significant predictor of DDIs. Prescribers should be more aware of potential DDIs. Future studies should assess potential DDIs in primary care over a longer period of time.
References
[1]
Mannheimer B, Ulfvarson J, Eklof S, Bergqvist M, Andersen-Karlsson E, et al. (2006) Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. Eur J Clin Pharmacol 62: 1075–1081.
[2]
Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, et al. (2004) Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 76: 85–96.
[3]
Bjerrum L, Andersen M, Petersen G, Kragstrup J (2003) Exposure to potential drug interactions in primary health care. Scand J Prim Health Care 21: 153–158.
[4]
Steinman MA, Hanlon JT (2010) Managing medications in clinically complex elders: “There's got to be a happy medium”. JAMA 304: 1592–1601.
[5]
Tatonetti NP, Denny JC, Murphy SN, Fernald GH, Krishnan G, et al. (2011) Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. Clin Pharmacol Ther 90: 133–142.
[6]
Seymour RM, Routledge PA (1998) Important drug-drug interactions in the elderly. Drugs Aging 12: 485–494.
[7]
Avery AJ, Sheikh A, Hurwitz B, Smeaton L, Chen YF, et al. (2002) Safer medicines management in primary care. Br J Gen Pract 52 Suppl: S17–22.
[8]
Zurakowski T (2009) The practicalities and pitfalls of polypharmacy. Nurse Pract 34: 36–41; quiz 41–32.
[9]
Linnarsson R (1993) Drug interactions in primary health care. A retrospective database study and its implications for the design of a computerized decision support system. Scand J Prim Health Care 11: 181–186.
[10]
Bjorkman IK, Fastbom J, Schmidt IK, Bernsten CB (2002) Pharmaceutical Care of the Elderly in Europe Research G (2002) Drug-drug interactions in the elderly. Ann Pharmacother 36: 1675–1681.
[11]
Doubova Dubova SV, Reyes-Morales H, Torres-Arreola Ldel P, Suarez-Ortega M (2007) Potential drug-drug and drug-disease interactions in prescriptions for ambulatory patients over 50 years of age in family medicine clinics in Mexico City. BMC Health Serv Res 7: 147.
[12]
Putnam W, Lawson B, Frail D, Bower K, Archibald G, et al. (2006) Potential for drug interactions in seniors with osteoarthritis. Can Fam Physician 52: 340–341.
[13]
Lopez-Picazo JJ, Ruiz JC, Sanchez JF, Ariza A, Aguilera B, et al. (2010) Prevalence and typology of potential drug interactions occurring in primary care patients. Eur J Gen Pract 16: 92–99.
[14]
Astrand B, Astrand E, Antonov K, Petersson G (2006) Detection of potential drug interactions - a model for a national pharmacy register. Eur J Clin Pharmacol 62: 749–756.
[15]
Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, et al. (2010) Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci 32: 187–193.
[16]
Egger SS, Drewe J, Schlienger RG (2003) Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58: 773–778.
[17]
Halkin H, Katzir I, Kurman I, Jan J, Malkin BB (2001) Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clin Pharmacol Ther 69: 260–265.
[18]
Lin CF, Wang CY, Bai CH (2011) Polypharmacy, aging and potential drug-drug interactions in outpatients in Taiwan: a retrospective computerized screening study. Drugs Aging 28: 219–225.
[19]
Schuler J, Duckelmann C, Beindl W, Prinz E, Michalski T, et al. (2008) Polypharmacy and inappropriate prescribing in elderly internal-medicine patients in Austria. Wien Klin Wochenschr 120: 733–741.
[20]
Secoli SR, Figueras A, Lebrao ML, de Lima FD, Santos JL (2010) Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging 27: 759–770.
[21]
Smithburger PL, Kane-Gill SL, Seybert AL (2010) Drug-drug interactions in cardiac and cardiothoracic intensive care units: an analysis of patients in an academic medical centre in the US. Drug Saf 33: 879–888.
[22]
Fokter N, Mo？ina M, Brvar M (2010) Potential drug-drug interactions and admissions due to drug-drug interactions in patients treated in medical departments. Wien Klin Wochenschr 122: 81–88.
[23]
Cruciol-Souza JM, Thomson JC (2006) A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics (Sao Paulo) 61: 515–520.
[24]
Bleich GW, Bleich A, Chiamulera P, Sanches AC, Schneider DS, et al. (2009) Frequency of potential interactions between drugs in medical prescriptions in a city in southern Brazil. Sao Paulo Med J 127: 206–210.
[25]
Miyasaka LS, Atallah AN (2003) Risk of drug interaction: combination of antidepressants and other drugs. Rev Saude Publica 37: 212–215.
[26]
Pivatto Júnior F, Godoy DB, Pires DFS, Pietrobon E, Rosa FTA, et al. (2009) Potential drug interactions among prescriptions of a teaching hospital in Porto Alegre. Rev AMRIGS 53: 251–256.
[27]
Silva NMO, Carvalho RP, Bernardes ACA, Moriel P, Mazzola PG, et al. (2010) Potential drug interaction evaluation in medical prescriptions in a public hospital specialized in women care, in Campinas, SP. Rev Ciênc Farm Básica Apl 31: 171–176.
[28]
Codagnone Neto V, Garcia VP, Santa Helena ET (2010) Possible pharmacological interactions in hypertensive and/or diabetic elderly in family health units at Blumenau (SC). Braz J Pharm Sci 46: 795–804.
[29]
Nobili A, Pasina L, Tettamanti M, Lucca U, Riva E, et al. (2009) Potentially severe drug interactions in elderly outpatients: results of an observational study of an administrative prescription database. J Clin Pharm Ther 34: 377–386.
[30]
Jankel CA, Speedie SM (1990) Detecting drug interactions: a review of the literature. DICP 24: 982–989.
[31]
Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, et al. (2004) Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (2003) 44: 136–141.
[32]
Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH (2005) Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf 28: 371–378.
[33]
Guedon-Moreau L, Ducrocq D, Duc MF, Quieureux Y, L'Hote C, et al. (2003) Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 59: 689–695.
[34]
Weingart SN, Toth M, Sands DZ, Aronson MD, Davis RB, et al. (2003) Physicians' decisions to override computerized drug alerts in primary care. Arch Intern Med 163: 2625–2631.
[35]
Lapi F, Vietri M, Moschini M, Cecchi E, Pugi A, et al. (2010) Potential drug-drug interactions and radiodiagnostic procedures: an in-hospital survey. Pharm World Sci 32: 200–205.
[36]
Magnus D, Rodgers S, Avery AJ (2002) GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther 27: 377–382.
[37]
Passarelli MC, Jacob-Filho W, Figueras A (2005) Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs Aging 22: 767–777.
[38]
Brvar M, Fokter N, Bunc M, Mozina M (2009) The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. BMC Clin Pharmacol 9: 8.
[39]
Viktil KK, Blix HS, Moger TA, Reikvam A (2007) Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol 63: 187–195.
[40]
Yang HJ, Choi MJ, Wen H, Kwon HN, Jung KH, et al. (2011) An effective assessment of simvastatin-induced toxicity with NMR-based metabonomics approach. PLoS One 6: e16641.
[41]
Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, et al. (2007) Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther 81: 679–684.
[42]
Morera T, Gervasini G, Carrillo JA, Benitez J (2005) Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions. Basic Clin Pharmacol Toxicol 96: 289–294.
[43]
Oshima Y (2011) Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med 50: 845–853.
[44]
Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, et al. (2007) Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf 16: 352–358.
[45]
Haueis P, Greil W, Huber M, Grohmann R, Kullak-Ublick GA, et al. (2011) Evaluation of drug interactions in a large sample of psychiatric inpatients: a data interface for mass analysis with clinical decision support software. Clin Pharmacol Ther 90: 588–596.
[46]
Mallet L, Spinewine A, Huang A (2007) The challenge of managing drug interactions in elderly people. Lancet 370: 185–191.
[47]
Paige NM, Nagami GT (2009) The top 10 things nephrologists wish every primary care physician knew. Mayo Clin Proc 84: 180–186.
[48]
Indermitte J, Burkolter S, Drewe J, Krahenbuhl S, Hersberger KE (2007) Risk factors associated with a high velocity of the development of hyperkalaemia in hospitalised patients. Drug Saf 30: 71–80.
[49]
Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, et al. (2009) A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 180: 713–718.
[50]
Kravitz RL, Ford DE (2008) Introduction: chronic medical conditions and depression–the view from primary care. Am J Med 121: S1–7.
[51]
Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329: 15–19.
[52]
de Abajo FJ, Montero D, Rodriguez LA, Madurga M (2006) Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 98: 304–310.
